信达生物(01801.HK)获摩根大通增持49.78万股

Group 1 - JPMorgan Chase & Co. increased its stake in Innovent Biologics (01801.HK) by purchasing 497,823 shares at an average price of HKD 82.2756 per share, totaling approximately HKD 40.96 million [1] - Following this transaction, JPMorgan's total holdings in Innovent Biologics rose to 87,249,744 shares, increasing its ownership percentage from 4.99% to 5.02% [1][3] - The transaction date for the increase in holdings was March 19, 2026, and the disclosure was made on March 24, 2026 [2][3]